What is the difference between AOD-9604 and IGF-1?

AOD-9604: AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. IGF-1: Binds IGF-1R with high affinity, activating PI3K/Akt and MAPK pathways promoting protein synthesis, satellite cell activation, and glucose uptake.

Is AOD-9604 FDA approved?

AOD-9604 is not evaluated or approved by the FDA. It is discussed for research and educational purposes only, not as medical guidance.

Is IGF-1 FDA approved?

IGF-1 is FDA approved (FDA status current as of 2005-08-30). This regulatory status is provided for research and educational context only.

How is AOD-9604 administered in research settings?

In research settings, AOD-9604 is typically administered via the subcutaneous or oral routes. PeptideBase does not provide dosing or administration instructions.

How is IGF-1 administered in research settings?

In research settings, IGF-1 is typically administered via the subcutaneous or intramuscular routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›AOD-9604 vs IGF-1

Peptide Comparison

AOD-9604 vs IGF-1

Name: AOD-9604 vs IGF-1 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

Both are GH / IGF Axis peptides.

AOD-9604

Advanced Obesity Drug 9604

Fat LossNot EvaluatedResearch Only

Half-life: 30–60 minutes

192 providers listed

Full AOD-9604 profile →

IGF-1

Insulin-like Growth Factor 1

PerformanceFDA ApprovedResearch Only

21 providers listed

Full IGF-1 profile →

Bottom line

IGF-1 is FDA-approved, while AOD-9604 is not evaluated — the clearest structural difference between them.

Quick Verdict

AOD-9604

Evidence

Emerging Evidence

Half-life

30–60 minutes

IGF-1

Evidence

Emerging Evidence

Half-life

—

Which One Should You Choose?

Your goal	Better option
Stronger clinical evidence	IGF-1
Further along in FDA review	IGF-1
Oral administration option	AOD-9604
Lower typical price per mg	AOD-9604
More provider options (192 vs 21)	AOD-9604

Research summary only — not medical advice. Consult a qualified provider before making any decisions.

Side-by-Side Comparison

AOD-9604

IGF-1

Mechanism Family

GH / IGF Axis

Half-life

30–60 minutes

—

FDA Status

not evaluated

approved

Admin Routes

subcutaneous, oral

subcutaneous, intramuscular

Availability

Research Only

Providers

192 listed

21 listed

FDA Update

—

Aug 2005

Avail. Notes

HGH fragment 176-191. Drug development terminated 2007 (Phase 3 failure). FDA GRAS notice GRN 000792 for food ingredient use only — not a drug approval. No active NDA. Research chemical.

—

Research Evidence

AOD-9604

PreclinicalAnimal · 1 key study · through 2001

IGF-1

Clinical (observational)Cohort study · 14 key studies · through 2026

Research Citations

AOD-9604

Animal2001 · Endocrinology

The effect of the growth hormone fragment AOD9604 on adipose tissue

IGF-1

Cohort2007 · Journal of Clinical Endocrinology and Metabolism

Long-term treatment with recombinant insulin-like growth factor (IGF)-I in children with severe IGF-I deficie…

Review2026 · Dig Dis

Early-onset colorectal cancer in Australia: environmental, microbial, and policy implications.

Cohort2026 · Pituitary

Speckle-tracking echocardiography reveals the synergistic impact of GH/IGF-1 excess and metabolic dysregulati…

Cohort2026 · Life Sci

Lacticaseibacillus parahuelsenbergensis THGS-36 alleviates acne-like inflammation and lipogenesis in sebocyte…

+10 more

About AOD-9604

AOD-9604 stimulates lipolysis and inhibits lipogenesis through mechanisms believed to be independent of the insulin-like growth factor pathway. It appears to mimic the fat-metabolising action of growth hormone without triggering the proliferative effects associated with full GH or GH-releasing peptides. Oral bioavailability has been observed in some formulations, making it of interest for non-injectable protocols.

Research Areas

selective fat tissue lipolysis via GH C-terminal fragment mechanismadipose metabolism stimulation without IGF-1 elevationoriginally developed to isolate GH lipolytic effect from growth effectssubcutaneous injection — reconstitution with bacteriostatic water required

About IGF-1

Binds IGF-1R with high affinity, activating PI3K/Akt and MAPK pathways promoting protein synthesis, satellite cell activation, and glucose uptake. Much shorter half-life (~15 min) than the LR3 analog (~20-30 hr) due to binding protein interactions.

Research Areas

muscle growthrecoveryfat metabolismtissue repairGH axis

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

AOD-9604

Contraindications

Pregnant Or Nursing

IGF-1

Contraindications

Active Cancer HistoryDiabetesPregnant Or Nursing

Price (per mg)

AOD-9604

$8.90/mg

$6.85 – $13.47 range

45 vendors

View price index →Find providers →

IGF-1

$65.00/mg

$42.65 – $70.99 range

14 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

AOD-9604

192 listed

Browse directory →

Providers offering

IGF-1

21 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

More GH / IGF Axis Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated July 3, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). AOD-9604 vs IGF-1 — Per-mg Price Comparison. Retrieved July 5, 2026, from https://peptidebase.io/peptides/compare/aod-9604/igf-1

https://peptidebase.io/peptides/compare/aod-9604/igf-1 Methodology License Download JSON Download CSV